Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impetine Gel vs Bactroban Ointment for paediatric impetigo
2024-517475-20-00Phase 3Authorised
- Sponsor
- Ojer Pharma
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Impetine in impetigo (2 arms), sponsored by Ojer Pharma. Primary endpoint: Clinical cure at end of follow-up (EOF). Planned start Jun 2025; status: authorised.
02
Drugs
Impetine
03
Conditions
impetigo
Beyond the preview
Go deeper on 2024-517475-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517475-20-00.